Displaying drugs 11176 - 11200 of 11745 in total
CB-010
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.
Investigational
Matched Description: … CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. …
MOD-5014
MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. It is being investigated for the treatment of hemophilia.
Investigational
Matched Description: … MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. …
HOV-12020
HOV-12020 is a palm tocotrienols complex being investigated for the treatment of cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).
Investigational
Matched Description: … HOV-12020 is a palm tocotrienols complex being investigated for the treatment of cerebral autosomal-dominant …
Povorcitinib
Povorcitinib is under investigation in clinical trial NCT06113445 (A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)).
Investigational
Matched Description: … Povorcitinib is under investigation in clinical trial NCT06113445 (A Study to Evaluate Efficacy and Safety …
Ecnoglutide
Ecnoglutide is under investigation in clinical trial NCT05813795 (A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity).
Investigational
Matched Description: … Ecnoglutide is under investigation in clinical trial NCT05813795 (A Phase 3 Study to Evaluate the Efficacy …
Rezvilutamide
Rezvilutamide is under investigation in clinical trial NCT05956639 (Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in Mhspc).
Investigational
Matched Description: … Rezvilutamide is under investigation in clinical trial NCT05956639 (Comparing a 6-month vs Long-term …
LGD2941
LGD2941 is a non-steroidal, selective androgen receptor modulator (SARM) developed jointly by Ligand and TAP.
Investigational
Matched Description: … LGD2941 is a non-steroidal, selective androgen receptor modulator (SARM) developed jointly by Ligand …
Flumequine
Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.
Withdrawn
Matched Description: … Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat …
Clorindione
Clorindione is a vitamin K antagonist, which may be useful to decrease prothrombin levels in humans.
Experimental
Matched Description: … Clorindione is a vitamin K antagonist, which may be useful to decrease prothrombin levels in humans. …
GsMtx-4
GsMtx-4 is a peptide found in tarantula venom that inhibits mechanosensitive ion channel (MSC) activity.
Investigational
Matched Description: … GsMtx-4 is a peptide found in tarantula venom that inhibits mechanosensitive ion channel (MSC) activity …
GIVI-MPC
GIVI-MPC is a therapy that uses human-induced pluripotent stem cell-derived myogenic progenitor cells.
Investigational
Matched Description: … GIVI-MPC is a therapy that uses human-induced pluripotent stem cell-derived myogenic progenitor cells …
P-42 peptide
P-42 peptide is a synthetic 23 amino acid peptide AASSGVSTPGSAGHDIITEQPRS derived from the Huntingtin protein
Investigational
Matched Description: … P-42 peptide is a synthetic 23 amino acid peptide AASSGVSTPGSAGHDIITEQPRS derived from the Huntingtin …
Licofelone
Developed by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a dual COX/LOX inhibitor and the first member of this new class of analgesic and anti-inflammatory drugs. It is currently under evaluation as a treatment for osteoarthritis (OA), the most common...
Investigational
Matched Description: … Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a ... It is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis …
PYM50018
PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in...
Investigational
Matched Description: … PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. ... When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle …
Plozalizumab
Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to...
Investigational
Matched Description: … Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found ... The recruitment of macrophages to the arterial wall is believed to be a critical step in the development …
SYNB1020
SYNB1020 is an engineered strain of Escherichia coli Nissle 1917 developed by Synlogic Inc. It was initially designed to convert ammonia to L-arginine and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016; however, the manufacturer discontinued further development of SYNB1020 to treat...
Investigational
Matched Description: … lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. ... however, the manufacturer discontinued further development of SYNB1020 to treat hyperammonemia due to a …
GDC-0425
GDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma).
Investigational
Matched Description: … GDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability …
Imgatuzumab
Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer).
Investigational
Matched Description: … Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination …
TT 173
TT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such as hemophilia and von Willebrand disease, as well as bleeding episodes in cutaneous injuries or dental procedures.
Investigational
Matched Description: … TT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such …
Ormeloxifene
Ormeloxifene is a third-generation selective estrogen receptor (ER) modulator. In India, ormeloxifene has been marketed since the 1990s as a non-hormonal, non-steroidal oral contraceptive taken once a week, and it was later introduced for the treatment of dysfunctional uterine bleeding. Similar to other selective estrogen receptor modulators (SERMs), ormeloxifene has...
Experimental
Matched Description: … Ormeloxifene is a third-generation selective estrogen receptor (ER) modulator. ... In India, ormeloxifene has been marketed since the 1990s as a non-hormonal, non-steroidal oral contraceptive ... [A251450,A251460] Ormeloxifene is marketed in India as a racemic mixture of the l- (levormeloxifene) …
Troxacitabine
Troxacitabine is a nucleoside analog with antineoplastic activity. There has been growing interest in its development for the treatment of patients with refractory lymphoproliferative conditions.
Investigational
Matched Description: … Troxacitabine is a nucleoside analog with antineoplastic activity. …
PV903
PV903 is a self administered vaginally delivered recombinant protein for the treatment of recurrent miscarriage, resulting from an intolerant immune response to the developing foetus.
Investigational
Matched Description: … PV903 is a self administered vaginally delivered recombinant protein for the treatment of recurrent miscarriage …
Strontium malonate
Strontium malonate is being developed as a novel orally available pharmaceutical for the treatment and prevention of osteoporosis. It is being developed by Osteologix Inc.
Investigational
Matched Description: … Strontium malonate is being developed as a novel orally available pharmaceutical for the treatment and …
Cetyl ethylhexanoate
Cetyl ethylhexanoate is an ester of cetyl alcohol and 2-ethylhexanoic acid. It is present in cosmetic products as a skin conditioning agent and emollient.
Experimental
Matched Description: … It is present in cosmetic products as a skin conditioning agent and emollient. …
Displaying drugs 11176 - 11200 of 11745 in total